Haemonetics (HAE) 10-Q2022 Q1 Quarterly report

Filed: 11 Aug 21, 6:57am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: amended, ASU, attributable, awaiting, broadly, call, capped, classification, consecutive, earlier, Entity, gathering, Indenture, index, inflationary, infrequent, intent, lender, lessor, manner, milestone, modified, noncompetitive, obsolete, outsourcing, pipeline, professional, recover, redeemed, relief, render, rest, retrospective, revised, royalty, senior, separated, spread, sterilization, stopping, successfully, trustee, unusual

Removed: alternative, arise, arrangement, authorization, broader, Carolina, cloud, commercially, commitment, computing, consummated, core, Corrupt, decline, declined, delay, delaying, deliver, delivering, eased, element, enabling, ensuring, EU, focused, forma, freeing, geography, health, heightened, hematology, hiring, immaterial, implementing, improvement, Initiative, launched, negatively, organic, organization, PCS, positioned, post, preserving, priority, pro, reach, reliable, reorganization, reorganized, replace, restricting, scale, South, spending, successful, supportable, sustainable, targeted, TEG, travel, turnaround

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated HAE transcripts

HAE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification Pursuant To

18 USC. Section 1350,

As Adopted Pursuant To

Section 906 of the Sarbanes/Oxley Act of 2002

In connection with the Quarterly Report of Haemonetics Corporation (the “Company”) on Form 10-Q for the period ended July 3, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher A. Simon, President and Chief Executive Officer of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 11, 2021

/s/ Christopher A. Simon

Christopher A. Simon,

President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange Commission or its staff upon request.